WFDC8 Inhibitors
The chemical class of WFDC8 inhibitors encompasses a spectrum of compounds characterized by diverse mechanisms of action, collectively exerting influence on the intricate regulatory networks governing WFDC8 within cellular contexts. WFDC8, a member of the WAP (Whey Acidic Protein) four-disulfide core domain family, plays a crucial role in modulating innate immune responses and is implicated in various cellular processes. Its expression and function are intricately regulated, making it an attractive target for modulation through chemical interventions. Sorafenib and Axitinib, classified as multi-kinase and tyrosine kinase inhibitors, respectively, operate by disrupting signaling cascades integral to cellular homeostasis. Sorafenib intervenes in the RAF/MEK/ERK pathway, while Axitinib perturbs VEGFRs, collectively altering the cellular milieu and impacting the regulatory landscape of WFDC8. Bortezomib, Niclosamide, and Rapamycin, possessing distinctive activities as proteasome inhibitors, Wnt/β-catenin disruptors, and mTOR inhibitors, respectively, exert their influence on cellular processes intersecting with WFDC8 regulation.
The compounds SB203580, Wortmannin, and SP600125, targeting p38 MAPK, PI3K/AKT, and JNK pathways, respectively, contribute to the indirect modulation of WFDC8 by affecting the interconnected signaling networks that converge on WFDC8 regulation. Dasatinib, Trametinib, LY294002, and PD98059, characterized as kinase inhibitors, disrupt Src kinases, MAPK/ERK, PI3K/AKT, and MEK pathways, respectively, thereby influencing the expression and function of WFDC8. This diverse chemical toolbox collectively equips researchers with valuable resources to meticulously explore the intricacies of cellular pathways, providing a nuanced understanding of the indirect modulation of WFDC8 and its multifaceted involvement in cellular signaling networks. The comprehensive elucidation of these chemical interactions significantly contributes to the advancement of our comprehension of WFDC8 regulation in various cellular contexts. The intricate interplay between these inhibitors and the cellular machinery sheds light on the dynamic regulatory mechanisms governing WFDC8, opening avenues for deeper exploration into the role of WFDC8 in cellular physiology and immune responses.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a multi-kinase inhibitor known for its role in dampening the RAF/MEK/ERK signaling pathway. By specifically targeting RAF kinases, it disrupts the downstream cascade, influencing cellular processes and indirectly modulating WFDC8 activity within the cell. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib, a proteasome inhibitor, disrupts protein degradation pathways. This indirectly affects WFDC8 levels by influencing the degradation rate of specific regulatory proteins involved in its modulation. The cellular proteostasis disruption induced by Bortezomib alters the equilibrium, impacting WFDC8 expression. | ||||||
Niclosamide | 50-65-7 | sc-250564 sc-250564A sc-250564B sc-250564C sc-250564D sc-250564E | 100 mg 1 g 10 g 100 g 1 kg 5 kg | $37.00 $77.00 $184.00 $510.00 $1224.00 $5814.00 | 8 | |
Niclosamide disrupts multiple cellular processes, including the Wnt/β-catenin signaling pathway. By indirectly modulating this pathway, Niclosamide alters the cellular context, impacting the regulation of WFDC8 and its involvement in signaling networks. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin, an mTOR inhibitor, disrupts the mTOR signaling pathway. Its influence on mTOR cascades indirectly modulates WFDC8 by altering the cellular processes governed by mTOR. The downstream effects of mTOR inhibition create a cellular environment that indirectly impacts the regulation of WFDC8. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580, a p38 MAPK inhibitor, affects the p38 MAPK signaling pathway. Its modulation of this pathway indirectly influences WFDC8, as p38 MAPK is involved in cellular responses that intersect with the regulatory networks of WFDC8. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin, a phosphoinositide 3-kinase (PI3K) inhibitor, disrupts the PI3K/AKT signaling pathway. Its impact on this pathway indirectly modulates WFDC8 by altering the cellular processes regulated by PI3K/AKT, thereby influencing the expression and function of WFDC8 within the cell. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib, a tyrosine kinase inhibitor, targets multiple kinases, including Src family kinases. Its influence on these kinases indirectly impacts WFDC8 regulation, as Src kinases are involved in signaling cascades that intersect with the pathways governing WFDC8 expression and function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, a JNK inhibitor, disrupts the JNK signaling pathway. Its modulation of this pathway indirectly influences WFDC8, as JNK is a crucial component of cellular responses that intersect with the regulatory networks of WFDC8. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
Trametinib, a MEK inhibitor, specifically targets the MAPK/ERK pathway. Its disruption of this pathway indirectly modulates WFDC8 by altering the cellular processes governed by MAPK/ERK, influencing the expression and function of WFDC8 within the cell. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002, a PI3K inhibitor, targets the PI3K/AKT signaling pathway. Its impact on this pathway indirectly modulates WFDC8 by altering the cellular processes regulated by PI3K/AKT, thereby influencing the expression and function of WFDC8 within the cell. | ||||||